Research Article
A Descriptive Correlational Study to Evaluate Three Measures of Assessing Upper Extremity Function in Individuals with Multiple Sclerosis
Table 1
Clinical-demographic profile of our study sample.
| | Variable | Frequencies (%) |
| | Sex | | | Females | 79 (70.5%) | | Males | 33 (29.5%) | | Mean age (year) | | | Mean age of onset (year) | | | Mean duration (year) | | | MS phenotype | | CIS | 3 (2.7%) | | RRMS | 71 (63.4%) | | SPMS | 23 (20.5%) | | PPMS | 15 (13.4%) | | Mean relapses per year (range) | | | Median EDSS | 2.75 | | Employment status | | Employed | 36 (32.1%) | | Long-term disability | 32 (28.6%) | | Retired | 14 (12.5%) | | Unemployed | 8 (7.1%) | | Adjusted employment | 2 (1.8%) | | Self-employed | 5 (4.5%) | | Unpaid employment | 2 (1.8%) | | Unknown | 13 (11.6%) | | MS DMTs | | Alemtuzumab | 9 (8.0%) | | Cladribine | 4 (3.6%) | | Dimethyl fumarate | 16 (14.3%) | | Fingolimod | 3 (2.7%) | | Glatiramer acetate | 9 (8.0%) | | Interferon beta-1a | 6 (5.4%) | | Natalizumab | 4 (3.6%) | | Ocrelizumab | 6 (5.4%) | | Peginterferon beta-1a | 1 (0.9%) | | Teriflunomide | 5 (4.5%) | | None | 49 (43.8%) |
|
|
Abbreviations: CIS: clinically isolated syndrome; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; EDSS: expanded disability status scale; MS DMTs: multiple sclerosis specific disease-modifying therapies.
|
